Meeting
2020 ASCO Virtual Scientific Program
Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.
Authors
Victor Moreno
START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain
Victor Moreno , Yohann Loriot , Piotr Rutkowski , Carmen Beato , Enriqueta Felip , Ignacio Duran , Dariusz Kowalski , Salvatore Siena , Diego Cortinovis , Lionnel Geoffrois , Elizabeth Ruth Plummer , Scott T. Tagawa , Emiliano Calvo , Begona Mellado , Anne OHagan , Sydney Akapame , Manish Monga , James Greger , Nebedita Bandyopadhyay , Arlene O. Siefker-Radtke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02908906 and NCT03473743
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3055)
DOI
10.1200/JCO.2020.38.15_suppl.3055
Abstract #
3055
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
![Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.](https://d201v5jt9ylckg.cloudfront.net/257/14745/183995/183995_poster_pv.jpg)
Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.
First Author: Victor Moreno
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.
First Author: Piotr Rutkowski
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe
Poster
2022 ASCO Annual Meeting
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
First Author: Nicholas Coupe